# Hangzhou Joinhealth Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-joinhealth-technology-co

- Industry: Software
- Headquarters: Hangzhou, China
- Website: www.lanniuh.com
- Total disclosed funding: $117M
- Latest round: Series B (Nov 8, 2021)
- Investors on record: 10

## About

Located in Hangzhou, China, Hangzhou Joinhealth Technology Co., LTD. is dedicated to advancing healthcare through innovative digital therapy solutions focused on post-disease management.Founded in 2015 in Hangzhou, China, Hangzhou Joinhealth Technology Co., LTD. specializes in digital therapy solutions for post-disease management. The company has successfully completed a total of 7 deals, with its most recent funding round occurring in November 2021. This Series B funding round attracted investment from Huaxing Growth Capital, 3H Health Investment Management (Hong Kong) Limited, and Sequoia Capital, raising a total of RMB 500 million. The company has not undergone any significant pivots or changes in strategy since its inception.Hangzhou Joinhealth Technology Co., Ltd. specializes in post-disease management solutions, leveraging advanced digital therapy technologies to enhance patient care and streamline healthcare operations. The company’s core offerings include a comprehensive health management platform that operates through a vast knowledge database, facilitating intelligent follow-up paths for disease management. With a client base exceeding 1,000 hospitals and partnerships with top-tier healthcare institutions, the company primarily serves hospitals and healthcare providers in China, delivering services designed to improve patient outcomes and optimize healthcare delivery. The platform supports over 20,000 online doctors and 100,000 online nurses, effectively addressing the needs of more than 200 million patients to ensure timely and efficient post-treatment care.Jianhai Technology's revenue generation model is predominantly based on B2B transactions, engaging in partnerships with hospitals and healthcare providers for the deployment of its healthcare management solutions. The company offers a subscription-based service structure that allows hospitals to access its digital therapy platforms and health management tools, thereby enhancing their operational capabilities and patient care services. Specific pricing plans for their services are not disclosed; however, the company’s partnerships suggest a tailored revenue-sharing model that aligns with the healthcare providers’ utilization of Jianhai’s technology. The flagship offerings, which include advanced post-disease management systems, are designed to complement hospitals' existing infrastructures, creating a mutually beneficial financial arrangement that supports ongoing innovation in healthcare delivery.In November 2021, Hangzhou Joinhealth Technology Co., LTD. raised RMB 500 million in Series B funding led by Huaxing Growth Capital, which will be utilized to strengthen their post-diagnosis disease management and service operation ecosystem. The company is focused on launching new products aimed at enhancing its health management capabilities, although specific release dates have not been disclosed. Additionally, plans are underway to expand into new markets, targeting regions beyond China by 2024.

## Funding rounds

- Series B, Nov 8, 2021, $78M — Hong Shan, China Renaissance, 3H Health Investment
- Series B, Mar 22, 2021, $23M — Hong Shan, Source Code Capital, Sherpa Healthcare Partners
- Series A, Sep 29, 2020, $8.8M — Source Code Capital, Sherpa Healthcare Partners
- Series A, Jun 18, 2020 — Sherpa Healthcare Partners
- Series A, Jul 25, 2019 — Haibang Venture, Sherpa Healthcare Partners, iFLYTEK, Lihan Capital
- Series A, Jun 27, 2018, $4.5M — G-Channel Investment
- Series A, Jun 9, 2017, $2.2M — Future Value Capital, Haibang Venture

## Investors

- Future Value Capital (https://capitalatlas.ai/funds/future-value-capital) — Series A
- Haibang Venture — Series A
- G-Channel Investment (https://capitalatlas.ai/funds/g-channel-investment) — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- iFLYTEK — Series A
- Lihan Capital — Series A
- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series A, Series B
- Hong Shan — Series B
- China Renaissance (https://capitalatlas.ai/funds/china-renaissance) — Series B
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series B